Known as a marker, the over-expression of HER2, a member of the epidermal growth factor receptor tyrosine kinase family, occurs in 25% of breast cancers, predict for poor clinical outcomes, and resistance to chemotherapies [60]–[62]. This evidence concerns the gene ERBB2 and breast cancer.